| scholarly article | Q13442814 |
| P356 | DOI | 10.1126/SCIENCE.1352912 |
| P698 | PubMed publication ID | 1352912 |
| P2093 | author name string | P. D. Greenberg | |
| C. R. Li | |||
| S. R. Riddell | |||
| J. M. Goodrich | |||
| K. S. Watanabe | |||
| M. E. Agha | |||
| P433 | issue | 5067 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 4 | |
| P304 | page(s) | 238-241 | |
| P577 | publication date | 1992-07-01 | |
| 1992-07-10 | |||
| P1433 | published in | Science | Q192864 |
| P1476 | title | Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones | |
| P478 | volume | 257 |
| Q37257276 | 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy |
| Q49115156 | 5(th) International Workshop on CMV and Immunosenescence - A shadow of cytomegalovirus infection on immunological memory. |
| Q40627421 | A CTL epitope from human cytomegalovirus IE1 defined by combining prediction of HLA binding and proteasomal processing is the target of dominant immune responses in patients after allogeneic stem cell transplantation |
| Q89142871 | A Diverse Lipid Antigen-Specific TCR Repertoire Is Clonally Expanded during Active Tuberculosis |
| Q38572657 | A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells |
| Q41203830 | A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes |
| Q35570091 | A Survival Game of Hide and Seek: Cytomegaloviruses and MHC Class I Antigen Presentation Pathways |
| Q33950824 | A comparison of cytomegalovirus and community respiratory viruses in immunocompromised patients |
| Q36241631 | A critical role for neutralizing-antibody-producing B cells, CD4(+) T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: implications for adoptive immunotherapy of virus carriers |
| Q36960167 | A cytomegalovirus inhibitor of gamma interferon signaling controls immunoproteasome induction |
| Q34625160 | A non-human primate model for analysis of safety, persistence, and function of adoptively transferred T cells |
| Q44211391 | A novel 'sort-suicide' fusion gene vector for T cell manipulation |
| Q36981848 | A novel virus carrier state to evaluate immunotherapeutic regimens: regulatory T cells modulate the pathogenicity of antiviral memory cells |
| Q30700012 | A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes |
| Q40205976 | A self-inactivating retrovector incorporating the IL-2 promoter for activation-induced transgene expression in genetically engineered T-cells |
| Q36903202 | A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy |
| Q40079187 | A synthetic human cytomegalovirus pp65-IE1 fusion antigen efficiently induces and expands virus specific T cells |
| Q35176366 | A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy |
| Q58700455 | Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA |
| Q36228210 | Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation |
| Q34350259 | Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma |
| Q39876405 | Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro. |
| Q42783189 | Adoptive Immunotherapy after Allogeneic Hematopoietic Progenitor Cell Transplantation: New Perspectives for Transfusion Medicine |
| Q39100204 | Adoptive T Cell Immunotherapy for Patients with Primary Immunodeficiency Disorders |
| Q52721827 | Adoptive T Cell Therapy for Epstein-Barr Virus Complications in Patients With Primary Immunodeficiency Disorders. |
| Q37810116 | Adoptive T-cell therapy for B-cell malignancies |
| Q27006934 | Adoptive T-cell therapy for Leukemia |
| Q34511623 | Adoptive T-cell therapy: adverse events and safety switches |
| Q37778694 | Adoptive cell therapy: genetic modification to redirect effector cell specificity. |
| Q24644774 | Adoptive cell transfer: a clinical path to effective cancer immunotherapy |
| Q37008216 | Adoptive cellular immunotherapy for childhood malignancies |
| Q39044990 | Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine. |
| Q40621588 | Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. |
| Q45752119 | Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts. |
| Q35836837 | Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections |
| Q35582326 | Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood |
| Q50030034 | Adoptive transfer of T lymphocytes |
| Q81398931 | Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants |
| Q79771975 | Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma |
| Q36403280 | Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers |
| Q42278604 | Adoptive transfer of cytomegalovirus-specific effector CD4+ T cells provides antiviral protection from murine CMV infection |
| Q36183567 | Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates |
| Q34223487 | Adoptive transfer of lymphocytes sensitized to the major surface glycoprotein of Pneumocystis carinii confers protection in the rat |
| Q34279672 | Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation |
| Q38170885 | Advances in chimeric antigen receptor immunotherapy for neuroblastoma |
| Q61195803 | Advances in immunotherapyfor prostate cancer |
| Q38202572 | Advances in the management of viral infections |
| Q90453872 | Advances in the treatment of cytomegalovirus |
| Q72004638 | Analysis of the role of CD4+ T-cells during murine cytomegalovirus infection in different strains of mice |
| Q36654615 | Anti-idiotypic mimicry of a neutralizing epitope on the glycoprotein B complex of human cytomegalovirus |
| Q36363051 | Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. |
| Q84952536 | Antigen presentation under the influence of 'immune evasion' proteins and its modulation by interferon-gamma: implications for immunotherapy of cytomegalovirus infection with antiviral CD8 T cells |
| Q24675502 | Antigen processing in vivo and the elicitation of primary CTL responses |
| Q78471193 | Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance |
| Q92864734 | At the Intersection of Biomaterials and Gene Therapy: Progress in Non-viral Delivery of Nucleic Acids |
| Q45762890 | Augmentation of cell-mediated immunotherapy against herpes simplex virus by interleukins: comparison of in vivo effects of IL-2 and IL-7 on adoptively transferred T cells |
| Q39180715 | BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies. |
| Q92178602 | Battle between Host Immune Cellular Responses and HCMV Immune Evasion |
| Q38169797 | Biology and pathogenesis of cytomegalovirus in periodontal disease |
| Q52562585 | Biomagnetic isolation of antigen-specific CD8+ T cells usable in immunotherapy. |
| Q34258584 | Biphasic role of 4-1BB in the regulation of mouse cytomegalovirus-specific CD8(+) T cells |
| Q24806112 | Blood and alveolar lymphocyte subsets in pulmonary cytomegalovirus infection after lung transplantation |
| Q35886838 | Bone marrow failure by cytomegalovirus is associated with an in vivo deficiency in the expression of essential stromal hemopoietin genes |
| Q50532976 | Brain-resident memory CD8+ T cells induced by congenital CMV infection prevent brain pathology and virus reactivation. |
| Q37953321 | Buffered memory: a hypothesis for the maintenance of functional, virus-specific CD8(+) T cells during cytomegalovirus infection |
| Q49340452 | CD1b Tetramers Identify T Cells that Recognize Natural and Synthetic Diacylated Sulfoglycolipids from Mycobacterium tuberculosis |
| Q45416113 | CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells |
| Q27022957 | CD4 T-cell immunotherapy for chronic viral infections and cancer |
| Q37559686 | CD4 and CD8 T cells mediate distinct lethal meningoencephalitis in mice challenged with Tacaribe arenavirus |
| Q37375643 | CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy |
| Q64450813 | CD8 T-Cell Immunotherapy of Cytomegalovirus Disease in the Murine Model |
| Q37111301 | CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept" provided by the murine model |
| Q41610140 | CD8+ cells in human immunodeficiency virus type I pathogenesis: cytolytic and noncytolytic inhibition of viral replication. |
| Q28073770 | CMV-Specific CD8 T Cell Differentiation and Localization: Implications for Adoptive Therapies |
| Q42181212 | CMV-specific T cell isolation from G-CSF mobilized peripheral blood: depletion of myeloid progenitors eliminates non-specific binding of MHC-multimers |
| Q99589832 | CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients |
| Q96591112 | CRISPR-Cas9-Mediated Glucocorticoid Resistance in Virus-Specific T Cells for Adoptive T Cell Therapy Posttransplantation |
| Q64051878 | CTL-mediated immunotherapy can suppress SHIV rebound in ART-free macaques |
| Q24676216 | Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes |
| Q40424152 | Cellular Adoptive Immunotherapy after Bone Marrow Transplantation |
| Q84669662 | Cellular Immunotherapy of Cancer |
| Q98735538 | Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation |
| Q34746964 | Cellular immune responses in transplantation-associated chronic viral infections. |
| Q52061964 | Cellular immune responses induced by in vivo priming with a lipid-conjugated multimeric antigen peptide. |
| Q38179174 | Cellular immune therapy for viral infections in transplant patients |
| Q40565585 | Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes |
| Q35998792 | Cellular immunotherapy for viral infection after HSC transplantation |
| Q36612643 | Cellular therapy following allogeneic stem-cell transplantation |
| Q45074152 | Changes in natural immunity during the course of HIV-1 infection |
| Q52036661 | Clinical significance of CMV-specific T helper responses in lung transplant recipients. |
| Q55259946 | Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts. |
| Q36029988 | Cloning and large-scale expansion of epitope-specific equine cytotoxic T lymphocytes using an anti-equine CD3 monoclonal antibody and human recombinant IL-2 |
| Q37047331 | Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient |
| Q40561085 | Common emergencies in cancer medicine: infectious and treatment-related syndromes, Part I. |
| Q36597392 | Comparison of naïve and central memory derived CD8(+) effector cell engraftment fitness and function following adoptive transfer |
| Q41440201 | Competition between T cells maintains clonal dominance during memory inflation induced by MCMV. |
| Q47111092 | Comprehensive Analysis of Cytomegalovirus pp65 Antigen-Specific CD8+ T Cell Responses According to Human Leukocyte Antigen Class I Allotypes and Intraindividual Dominance |
| Q92700219 | Comprehensive Characterization of a Next-Generation Antiviral T-Cell Product and Feasibility for Application in Immunosuppressed Transplant Patients |
| Q92258584 | Conservation of molecular and cellular phenotypes of invariant NKT cells between humans and non-human primates |
| Q45870279 | Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy |
| Q35653625 | Constitutive activation of the interleukin 2 gene in the induction of spontaneous in vitro transformation and tumorigenicity of T cells |
| Q33784524 | Control of cytomegalovirus in bone marrow transplantation chimeras lacking the prevailing antigen-presenting molecule in recipient tissues rests primarily on recipient-derived CD8 T cells |
| Q33783800 | Control of murine cytomegalovirus in the lungs: relative but not absolute immunodominance of the immediate-early 1 nonapeptide during the antiviral cytolytic T-lymphocyte response in pulmonary infiltrates |
| Q33820695 | Controlling cytomegalovirus: helping the immune system take the lead |
| Q24290869 | Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells |
| Q35020384 | Cross-reactivity of HLA-B*1801-restricted T-lymphocyte clones with target cells expressing variants of the human cytomegalovirus 72kDa-IE1 protein. |
| Q27024456 | Current translational and clinical practices in hematopoietic cell and gene therapy |
| Q90513799 | Cytokine Networks and Survivin Peptide-Specific Cellular Immune Responses Predict Improved Survival in Patients With Glioblastoma Multiforme |
| Q40739408 | Cytomegaloviral virus infection in bone marrow transplantation recipients: strategies for prevention and treatment |
| Q46693840 | Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab |
| Q40424165 | Cytomegalovirus Infection in Marrow Transplantation |
| Q59356039 | Cytomegalovirus Infection: Mouse Model |
| Q92446001 | Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy |
| Q38703382 | Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector. |
| Q74302230 | Cytomegalovirus as a cause of very late interstitial pneumonia after bone marrow transplantation |
| Q73407599 | Cytomegalovirus diagnosis in renal and bone marrow transplant recipients: the impact of molecular assays |
| Q36436978 | Cytomegalovirus encodes a potent alpha chemokine |
| Q41909122 | Cytomegalovirus expresses the chemokine homologue vXCL1 capable of attracting XCR1+ CD4- dendritic cells. |
| Q39811091 | Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques. |
| Q43920822 | Cytomegalovirus pneumonia prior to engraftment following T-cell depleted bone marrow transplantation |
| Q94564147 | Cytomegalovirus-Associated Inhibition of Hematopoiesis Is Preventable by Cytoimmunotherapy With Antiviral CD8 T Cells |
| Q52564628 | Cytomegalovirus-Specific CD8+ T-Cells With Different T-Cell Receptor Affinities Segregate T-Cell Phenotypes and Correlate With Chronic Graft-Versus-Host Disease in Patients Post-Hematopoietic Stem Cell Transplantation. |
| Q47221262 | Cytomegalovirus-Specific T Cells Restricted by HLA-Cw*0702 Increase Markedly with Age and Dominate the CD8+ T-Cell Repertoire in Older People. |
| Q73979945 | Cytomegalovirus: the taming of the beast? |
| Q43555422 | Dendritic cell function after gene transfer with adenovirus-calcium phosphate co-precipitates |
| Q33807009 | Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression |
| Q40343848 | Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes. |
| Q38170500 | Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells |
| Q45780856 | Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors |
| Q36819337 | Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies |
| Q34262249 | Diverse specificities, phenotypes, and antiviral activities of cytomegalovirus-specific CD8+ T cells |
| Q37095344 | Dynamics of T cell memory in human cytomegalovirus infection |
| Q27489813 | Dynamics of the CD8 T-cell response following yellow fever virus 17D immunization |
| Q37091612 | Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients |
| Q59360867 | Efficient Delivery of Human Cytomegalovirus T Cell Antigens by Attenuated Sendai Virus Vectors |
| Q33851742 | Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. |
| Q30459034 | Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options |
| Q36403664 | Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL |
| Q37651700 | Enforced OX40 Stimulation Empowers Booster Vaccines to Induce Effective CD4+ and CD8+ T Cell Responses against Mouse Cytomegalovirus Infection |
| Q38266264 | Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes |
| Q33812288 | Enrichment of immediate-early 1 (m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62L(lo) memory-effector cell pool during latent murine cytomegalovirus infection of the lungs |
| Q46702297 | Epitope-specific in vivo protection against cytomegalovirus disease by CD8 T cells in the murine model of preemptive immunotherapy |
| Q44817209 | Escherichia coli-nitroreductase suicide gene control of human telomerase reverse transcriptase-transduced minor histocompatibility antigen-specific cytotoxic T cells |
| Q35693349 | Evaluating Human T-Cell Therapy of Cytomegalovirus Organ Disease in HLA-Transgenic Mice |
| Q40753339 | Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. |
| Q55462188 | Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. |
| Q64377789 | Ex vivo stimulation of cytomegalovirus (CMV)‐specific T cells using CMV pp65‐modified dendritic cells as stimulators |
| Q43507906 | Exhaustion of cytotoxic T cells during adoptive immunotherapy of virus carrier mice can be prevented by B cells or CD4+ T cells |
| Q36305254 | Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus |
| Q42176262 | Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation |
| Q43225933 | Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation |
| Q33843590 | Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65). |
| Q34163218 | Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia |
| Q37098062 | Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy |
| Q24793218 | Expression of the UL16 glycoprotein of Human Cytomegalovirus protects the virus-infected cell from attack by natural killer cells |
| Q71698411 | Fluorescence in situ hybridization with cosmid clones for the detection of human cytomegalovirus DNA in peripheral blood leukocytes |
| Q33917368 | Functional CD8 T cell memory responding to persistent latent infection is maintained for life |
| Q45867362 | Functional long-term thymidine kinase suicide gene expression in human T cells using a herpesvirus saimiri vector |
| Q33992464 | Gene therapy for infectious diseases |
| Q46137070 | Generation and in vivo persistence of polarized Th1 and Th2 memory cells |
| Q72296831 | Generation of antigen-specific CD4+ T cell lines from naive precursors |
| Q33803064 | Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: a tool to study the fine specificity of the antiviral response |
| Q40447738 | Generation of cytotoxic T cell responses directed to human leucocyte antigen Class I restricted epitopes from the Aspergillus f16 allergen. |
| Q53471048 | Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. |
| Q36551911 | Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients |
| Q35826514 | Genetic modification of T lymphocytes for adoptive immunotherapy |
| Q35591430 | Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells |
| Q33181048 | Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. |
| Q92462748 | Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7) |
| Q35029956 | HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo |
| Q30452144 | HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2 |
| Q57158932 | HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells |
| Q36371913 | HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ T cells |
| Q34253590 | Haematopoietic cell transplantation as immunotherapy |
| Q44625718 | Haploidentical stem cell transplantation with purified CD34 cells after a chemotherapy-alone conditioning regimen |
| Q35613477 | Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells |
| Q35391415 | High efficiency ex vivo cloning of antigen-specific human effector T cells |
| Q33755031 | Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting |
| Q40698555 | Host defenses against respiratory infection. |
| Q34289143 | Host immune responses to a viral immune modulating protein: immunogenicity of viral interleukin-10 in rhesus cytomegalovirus-infected rhesus macaques. |
| Q41108749 | Host immunologic augmentation for the control of infection |
| Q40675122 | How DNA viruses perturb functional MHC expression to alter immune recognition. |
| Q28069489 | How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients |
| Q38432092 | How understanding immunology contributes to managing CMV disease in immunosuppressed patients: now and in future |
| Q92700078 | Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients |
| Q36365868 | Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice |
| Q34785626 | Human Mycobacterium tuberculosis CD8 T Cell Antigens/Epitopes Identified by a Proteomic Peptide Library |
| Q35880866 | Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains. |
| Q37807749 | Human cytomegalovirus immunity and immune evasion |
| Q37104744 | Human cytomegalovirus infection and antiviral immunity in septic patients without canonical immunosuppression |
| Q35018043 | Human cytomegalovirus latency-associated proteins elicit immune-suppressive IL-10 producing CD4⁺ T cells |
| Q36684512 | Human cytomegalovirus-encoded interleukin-10 homolog inhibits maturation of dendritic cells and alters their functionality |
| Q35558537 | Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation |
| Q35965038 | Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. |
| Q33724256 | Human immunodeficiency virus (HIV)-specific gamma interferon secretion directed against all expressed HIV genes: relationship to rate of CD4 decline |
| Q33627502 | Human mucosal associated invariant T cells detect bacterially infected cells |
| Q30834544 | Human neonatal dendritic cells are competent in MHC class I antigen processing and presentation |
| Q34162822 | Humoral and cellular CMV responses in healthy donors; identification of a frequent population of CMV-specific, CD4+ T cells in seronegative donors |
| Q40746828 | IL-10 restricts memory T cell inflation during cytomegalovirus infection |
| Q36447548 | IL-12-Dependent Cytomegalovirus-Specific CD4+ T Cell Proliferation, T-bet Induction, and Effector Multifunction during Primary Infection Are Key Determinants for Early Immune Control |
| Q36767295 | IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. |
| Q35156297 | Identification and HLA-tetramer-validation of human CD4+ and CD8+ T cell responses against HCMV proteins IE1 and IE2. |
| Q36908561 | Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy |
| Q37336046 | Identification of HLA-A*2402-restricted HCMV immediate early-1 (IE-1) epitopes as targets for CD8+ HCMV-specific cytotoxic T lymphocytes |
| Q40726180 | Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus |
| Q45367705 | Identification of immunodominant T-cell epitopes in membrane protein of highly pathogenic porcine reproductive and respiratory syndrome virus |
| Q37629731 | Identification of the promoter of the mouse obese gene |
| Q34467405 | Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. |
| Q35872401 | Identification, analysis, and evolutionary relationships of the putative murine cytomegalovirus homologs of the human cytomegalovirus UL82 (pp71) and UL83 (pp65) matrix phosphoproteins |
| Q84971601 | Immune control in the absence of immunodominant epitopes: implications for immunotherapy of cytomegalovirus infection with antiviral CD8 T cells |
| Q89655603 | Immune engineering: from systems immunology to engineering immunity |
| Q37356040 | Immune evasion proteins enhance cytomegalovirus latency in the lungs. |
| Q33614398 | Immune evasion proteins of murine cytomegalovirus preferentially affect cell surface display of recently generated peptide presentation complexes |
| Q26827409 | Immune response to HHV-6 and implications for immunotherapy |
| Q34711496 | Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection |
| Q99238982 | Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies |
| Q37127201 | Immunity to Polyomavirus BK Infection: Immune Monitoring to Regulate the Balance between Risk of BKV Nephropathy and Induction of Alloimmunity |
| Q34426299 | Immunity to cytomegalovirus in early life. |
| Q37050965 | Immunobiology of human cytomegalovirus: from bench to bedside. |
| Q37399992 | Immunomodulation in the treatment of haematological malignancies |
| Q36498133 | Immunomodulatory properties of a viral homolog of human interleukin-10 expressed by human cytomegalovirus during the latent phase of infection. |
| Q36375893 | Immunotherapeutic relief from persistent infections and amyloid disorders. |
| Q36786033 | Immunotherapy by allogeneic stem cell transplantation |
| Q38514499 | Immunotherapy for viral and fungal infections. |
| Q44636718 | Immunotherapy of cytomegalovirus infection after stem-cell transplantation: a new option? |
| Q35958223 | Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia |
| Q33941012 | Immunotherapy: opportunities, risks and future perspectives |
| Q42265908 | Impact of T cell selection methods in the success of clinical adoptive immunotherapy |
| Q37186903 | In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). |
| Q37798997 | In vivo impact of cytomegalovirus evasion of CD8 T-cell immunity: facts and thoughts based on murine models. |
| Q47995100 | In vivo migration and function of transferred HIV-1-specific cytotoxic T cells |
| Q36365628 | Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses |
| Q28486852 | Individual RD1-region genes are required for export of ESAT-6/CFP-10 and for virulence of Mycobacterium tuberculosis |
| Q43040853 | Induction in vitro of a primary human antiviral cytotoxic T cell response |
| Q34796892 | Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells |
| Q42981208 | Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus |
| Q41130455 | Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen |
| Q46126414 | Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide |
| Q37708023 | Induction/engineering, detection, selection, and expansion of clinical-grade human antigen-specific CD8 cytotoxic T cell clones for adoptive immunotherapy |
| Q34229490 | Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells |
| Q54214517 | Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients. |
| Q44743006 | Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. |
| Q37200886 | Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. |
| Q94465337 | Insufficient Antigen Presentation Due to Viral Immune Evasion Explains Lethal Cytomegalovirus Organ Disease After Allogeneic Hematopoietic Cell Transplantation |
| Q40682309 | Intact antigen presentation for Epstein-Barr virus (EBV)-specific CTL by a lymphoblastoid cell line established from a patient with severe chronic active EBV infection |
| Q37081007 | Interplay between human cytomegalovirus and dendritic cells in T cell activation |
| Q60746748 | Interstitial pneumonitis in bone marrow transplant recipients is associated with local production of TH2-type cytokines and lack of T cell-mediated cytotoxicity |
| Q34556966 | Is human cell therapy research caught in a mousetrap? |
| Q34934444 | Is there a formula for an effective CMV vaccine? |
| Q45864147 | Isolating cytomegalovirus-specific T cells for adoptive transfer: are we there yet? |
| Q78385063 | Isolation and expansion of human cytomegalovirus- specific cytotoxic T lymphocytes using interferon-gamma secretion assay |
| Q37490823 | Isolation of highly suppressive CD25+FoxP3+ T regulatory cells from G-CSF-mobilized donors with retention of cytotoxic anti-viral CTLs: application for multi-functional immunotherapy post stem cell transplantation |
| Q36165605 | Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes |
| Q84115618 | Kinetics of ocular and systemic antigen-specific T-cell responses elicited during murine cytomegalovirus retinitis |
| Q33382369 | Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation |
| Q44335250 | Location of T-cell epitopes in nonstructural proteins 9 and 10 of type-II porcine reproductive and respiratory syndrome virus. |
| Q36835155 | Long-term expansion of effector/memory Vdelta2-gammadelta T cells is a specific blood signature of CMV infection |
| Q36361920 | Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain |
| Q43882001 | MHC class I-subversive gene functions of cytomegalovirus and their regulation by interferons-an intricate balance |
| Q33810440 | Macrophages escape inhibition of major histocompatibility complex class I-dependent antigen presentation by cytomegalovirus |
| Q52023787 | Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients. |
| Q59335092 | Major TCR Repertoire Perturbation by Immunodominant HLA-B44:03-Restricted CMV-Specific T Cells |
| Q40869910 | Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects |
| Q38342824 | Mast cells: innate attractors recruiting protective CD8 T cells to sites of cytomegalovirus infection. |
| Q34294829 | Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. |
| Q36384572 | Memory T cells specific for murine cytomegalovirus re-emerge after multiple challenges and recapitulate immunity in various adoptive transfer scenarios. |
| Q36400815 | Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog |
| Q34318010 | Molecules and mechanisms of the graft-versus-leukaemia effect |
| Q45862722 | Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals |
| Q60913862 | Mouse Model of Cytomegalovirus Disease and Immunotherapy in the Immunocompromised Host: Predictions for Medical Translation that Survived the "Test of Time" |
| Q37677563 | Mouse models in bone marrow transplantation and adoptive cellular therapy |
| Q39871175 | Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains |
| Q33809769 | Murine model of interstitial cytomegalovirus pneumonia in syngeneic bone marrow transplantation: persistence of protective pulmonary CD8-T-cell infiltrates after clearance of acute infection |
| Q34729631 | Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. |
| Q26740328 | Mutual Interference between Cytomegalovirus and Reconstitution of Protective Immunity after Hematopoietic Cell Transplantation |
| Q47631107 | Mycobacterium tuberculosis-specific CD8+ T cells preferentially recognize heavily infected cells |
| Q55094448 | Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma. |
| Q28730418 | Novel serial positive enrichment technology enables clinical multiparameter cell sorting |
| Q33713932 | Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. |
| Q64086953 | Opportunities to Target the Life Cycle of Epstein-Barr Virus (EBV) in EBV-Associated Lymphoproliferative Disorders |
| Q92643256 | Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function |
| Q38042835 | Parameters determining the efficacy of adoptive CD8 T-cell therapy of cytomegalovirus infection. |
| Q34300932 | Paths to stemness: building the ultimate antitumour T cell. |
| Q36377141 | Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. |
| Q33703139 | Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses |
| Q38353123 | Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells |
| Q52060127 | Peripheral clonal deletion of antiviral memory CD8+ T cells. |
| Q52010634 | Persistent lack of human herpesvirus-6 specific T-helper cell response in liver transplant recipients. |
| Q43433013 | Persistent rat cytomegalovirus (RCMV) infection of the salivary glands contributes to the anti-RCMV humoral immune response |
| Q36814589 | Pharmacotherapy versus T lymphocytes for CMV. |
| Q85157571 | Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient |
| Q47550219 | Posttransplant chimeric antigen receptor therapy |
| Q42151049 | Predictable alphabeta T-cell receptor selection toward an HLA-B*3501-restricted human cytomegalovirus epitope |
| Q33782273 | Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence |
| Q36315607 | Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant. |
| Q36453570 | Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials |
| Q35558815 | Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants |
| Q34339686 | Processing and presentation of murine cytomegalovirus pORFm164-derived peptide in fibroblasts in the face of all viral immunosubversive early gene functions |
| Q27314843 | Proliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaques |
| Q45116400 | Prophylaxis: the foundation for our future progress |
| Q35041705 | Prospects for immunotherapy of malignant disease |
| Q38926265 | Prospects of a vaccine for the prevention of congenital cytomegalovirus disease |
| Q73028738 | Quantification of replication of clinical cytomegalovirus isolates in cultured endothelial cells and fibroblasts by a focus expansion assay |
| Q33588711 | Re-adapting T cells for cancer therapy: from mouse models to clinical trials |
| Q28079823 | Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications |
| Q37095341 | Recombinant viruses as tools to study human cytomegalovirus immune modulation |
| Q36999665 | Reconstitution of CD8 T Cells Protective against Cytomegalovirus in a Mouse Model of Hematopoietic Cell Transplantation: Dynamics and Inessentiality of Epitope Immunodominance. |
| Q83225298 | Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT |
| Q72059554 | Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor |
| Q81261927 | Reconstitution of HLA-A*2402-restricted cytomegalovirus-specific T-cells following stem cell transplantation |
| Q38931391 | Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool |
| Q41866420 | Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I |
| Q92621798 | Releasing the concept of HLA-allele specific peptide anchors in viral infections: A non-canonical naturally presented human cytomegalovirus-derived HLA-A*24:02 restricted peptide drives exquisite immunogenicity |
| Q36399914 | Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease |
| Q50097987 | Reprint of: Virus-Specific T Cells: Broadening Applicability |
| Q58657735 | Requirement for neutralizing antibodies to control bone marrow transplantation-associated persistent viral infection and to reduce immunopathology |
| Q42364280 | Retroviral transfer of T-cell receptor genes produces cells with a broad range of lytic activity |
| Q53940326 | Rev activity determines sensitivity of HIV-1-infected primary T cells to CTL killing. |
| Q34495529 | Reverse genetics modification of cytomegalovirus antigenicity and immunogenicity by CD8 T-cell epitope deletion and insertion |
| Q60029223 | Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection |
| Q58328348 | Role of Cellular Immunity in Protection against HIV Infection**This article was accepted for publication on 31 October 1996 |
| Q57176933 | Role of Epstein-Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target |
| Q91774706 | Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients |
| Q33217629 | Selection of CMV-specific CD8+ and CD4+ T cells by mini-EBV-transformed B cell lines |
| Q37629901 | Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. |
| Q36648290 | Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. |
| Q35794646 | Separating antiviral and GVHD activities of donor T cells prior to bone marrow transplantation |
| Q40662000 | Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes |
| Q93104450 | Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy |
| Q27002575 | Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? |
| Q34769333 | Stem cell-based anti-HIV gene therapy |
| Q61798868 | Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation |
| Q36673260 | Subdominant CD8 T-cell epitopes account for protection against cytomegalovirus independent of immunodomination |
| Q36369054 | Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection |
| Q53350069 | Summary of the II International Symposium on Cytomegalovirus. |
| Q73574832 | Suppression of human hepatoma in mice through adoptive transfer of immunity to the hepatitis B surface antigen |
| Q35068768 | Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins |
| Q30577136 | Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal. |
| Q33845720 | Systemic hematogenous maintenance of memory inflation by MCMV infection. |
| Q34510551 | T cell immunotherapeutic populations control viral infections in bone marrow transplant recipients |
| Q93001461 | T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant |
| Q38815977 | T cell responses to cytomegalovirus |
| Q37382387 | T cell susceptibility to HIV influences outcome of opportunistic infections |
| Q36821993 | T cell therapies following hematopoietic stem cell transplantation: surely there must be a better way than DLI? |
| Q39898534 | T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor. |
| Q37058107 | T cells for viral infections after allogeneic hematopoietic stem cell transplant |
| Q34414412 | T cells take aim at cancer |
| Q26786661 | T-Cell Therapy: Options for Infectious Diseases |
| Q92525198 | T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes |
| Q34550760 | T-bet:Eomes balance, effector function, and proliferation of cytomegalovirus-specific CD8+ T cells during primary infection differentiates the capacity for durable immune control |
| Q36234904 | T-cell genetic modification for re-directed tumor recognition. |
| Q45876112 | T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients |
| Q36087036 | T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up! |
| Q37798704 | T-cell therapy for cytomegalovirus infection |
| Q36142522 | T-cell therapy for viral infections following transplantation: why stop at three viruses? |
| Q37220602 | Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody. |
| Q24670153 | Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization |
| Q36116754 | The Cellular Localization of Human Cytomegalovirus Glycoprotein Expression Greatly Influences the Frequency and Functional Phenotype of Specific CD4+ T Cell Responses |
| Q39130457 | The Principles of Engineering Immune Cells to Treat Cancer |
| Q33734872 | The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches. |
| Q35477534 | The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation |
| Q36735379 | The continuing contribution of gene marking to cell and gene therapy. |
| Q41887918 | The efficacy of antigen processing is critical for protection against cytomegalovirus disease in the presence of viral immune evasion proteins. |
| Q36242361 | The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. |
| Q33970944 | The immunogenicity of human and murine cytomegaloviruses |
| Q27692570 | The immunological underpinnings of vaccinations to prevent cytomegalovirus disease |
| Q56917311 | The impact of HLA-B micropolymorphism outside primary peptide anchor pockets on the CTL response to CMV |
| Q73722298 | The impact of psychological stress on the efficacy of anti-viral adoptive immunotherapy in an immunocompromised host |
| Q36384707 | The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation |
| Q35709655 | The many important facets of T-cell repertoire diversity |
| Q39551804 | The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo |
| Q38049899 | The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB. |
| Q33797749 | The putative natural killer decoy early gene m04 (gp34) of murine cytomegalovirus encodes an antigenic peptide recognized by protective antiviral CD8 T cells |
| Q33781851 | The relative role of lymphocyte granule exocytosis versus death receptor-mediated cytotoxicity in viral pathophysiology |
| Q41435458 | The role of cytotoxic T lymphocytes in the evolution of genetically stable viruses |
| Q37592177 | The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care |
| Q61851835 | The use of Teflon cell culture bags to expand functionally active CD8+ cytotoxic T lymphocytes |
| Q41115110 | The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens |
| Q40199809 | Therapeutic T cell engineering |
| Q92735537 | Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction |
| Q27308832 | Therapeutic antiviral T cells noncytopathically clear persistently infected microglia after conversion into antigen-presenting cells |
| Q34786691 | Therapeutic cancer vaccines: are we there yet? |
| Q37333710 | Therapeutic memory T cells require costimulation for effective clearance of a persistent viral infection. |
| Q44026468 | Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells |
| Q54321271 | Transfection of dendritic cells with in vitro-transcribed CMV RNA induces polyclonal CD8+- and CD4+-mediated CMV-specific T cell responses. |
| Q71803154 | Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression |
| Q41349219 | Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor |
| Q33811112 | Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes |
| Q36919619 | Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients |
| Q35849686 | Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype |
| Q36884194 | Translational mini-review series on infectious disease: congenital cytomegalovirus infection: 50 years on. |
| Q34554722 | Treatment of Epstein-Barr virus-associated malignancies with specific T cells |
| Q45472170 | Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation |
| Q45730808 | Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells |
| Q37419728 | Treatment of lymphoma with adoptively transferred T cells. |
| Q37808467 | Tumor vaccines and beyond |
| Q44696017 | Two types of CMV-specific memory responses in lung transplant recipients |
| Q38514503 | Umbilical cord blood graft engineering: challenges and opportunities. |
| Q37837487 | Understanding human T-cell-mediated immunoregulation through herpesviruses |
| Q44618759 | Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation |
| Q35751946 | Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. |
| Q52717409 | Validation of a CD1b tetramer assay for studies of human mycobacterial infection or vaccination. |
| Q24646943 | Viral immune evasion due to persistence of activated T cells without effector function |
| Q35962532 | Viral prophylaxis in organ transplant patients |
| Q38074019 | Viral-specific adoptive immunotherapy after allo-SCT: the role of multimer-based selection strategies |
| Q98291353 | Virus-Specific T Cell Therapies for HIV: Lessons Learned From Hematopoietic Stem Cell Transplantation |
| Q45326335 | Virus-Specific T Cells: Broadening Applicability |
| Q38797555 | Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections |
| Q83139492 | [131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity |
Search more.